ACRS (Aclaris Therapeutics) Cyclically Adjusted Book per Share: $3.99 (As of Mar. 2026)


ACRS Aclaris Therapeutics Inc ACRS
38 GF Score
Price $5.04
GF Value $0.45
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Cyclically Adjusted Book per Share?

Aclaris Therapeutics ACRS +0.40% 38 Cyclically Adjusted Book per Share is $3.99 as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aclaris Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $1.029. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Aclaris Therapeutics's average Cyclically Adjusted Book Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-30), Aclaris Therapeutics's current stock price is $5.035. Aclaris Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $3.99. Aclaris Therapeutics's Cyclically Adjusted PB Ratio of today is 1.26.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aclaris Therapeutics was 1.26. The lowest was 0.26. And the median was 0.48.


Aclaris Therapeutics  (NAS:ACRS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aclaris Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.035/3.99
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aclaris Therapeutics was 1.26. The lowest was 0.26. And the median was 0.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aclaris Therapeutics Cyclically Adjusted Book per Share Related Terms


Aclaris Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Cyclically Adjusted Book per Share Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 4.02 4.03

Aclaris Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.05 4.17 4.03 3.99

ACRS vs RLMD, GYRE, SGP: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Aclaris Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PB Ratio falls into.


ACRS
38GF Score
Aclaris Therapeutics Inc ACRS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.029/330.2130*330.2130
=1.029

Current CPI (Mar. 2026) = 330.2130.

Aclaris Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.216 241.018 5.776
201609 3.787 241.428 5.180
201612 6.504 241.432 8.896
201703 6.142 243.801 8.319
201706 6.289 244.955 8.478
201709 7.921 246.819 10.597
201712 7.300 246.524 9.778
201803 6.487 249.554 8.584
201806 5.626 251.989 7.372
201809 4.722 252.439 6.177
201812 5.220 251.233 6.861
201903 4.416 254.202 5.736
201906 3.324 256.143 4.285
201909 2.061 256.759 2.651
201912 1.685 256.974 2.165
202003 1.402 258.115 1.794
202006 1.156 257.797 1.481
202009 0.950 260.280 1.205
202012 0.835 260.474 1.059
202103 2.156 264.877 2.688
202106 3.820 271.696 4.643
202109 3.537 274.310 4.258
202112 3.223 278.802 3.817
202203 2.919 287.504 3.353
202206 3.536 296.311 3.941
202209 3.297 296.808 3.668
202212 2.963 296.797 3.297
202303 2.631 301.836 2.878
202306 2.540 305.109 2.749
202309 2.208 307.789 2.369
202312 2.217 306.746 2.387
202403 1.993 312.332 2.107
202406 1.876 314.175 1.972
202409 1.822 315.301 1.908
202412 1.442 315.605 1.509
202503 1.331 319.799 1.374
202506 1.216 322.561 1.245
202509 1.109 324.800 1.127
202512 0.855 324.054 0.871
202603 1.029 330.213 1.029

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.99 mean?
Aclaris Therapeutics (ACRS) has a Cyclically Adjusted Book per Share of $3.99 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Cyclically Adjusted Book per Share too high?
Aclaris Therapeutics' current Cyclically Adjusted Book per Share is $3.99. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Cyclically Adjusted Book per Share compare to RLMD and GYRE?
Aclaris Therapeutics' Cyclically Adjusted Book per Share of $3.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Cyclically Adjusted Book per Share is $3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.04 — trading 1018.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $3.99. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Cyclically Adjusted Book per Share is $3.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.04 is trading 1018.9% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Cyclically Adjusted Book per Share: $3.99
  • GF Value™: $0.45 vs. price of $5.04 (1018.9% above fair value)
  • GF Score™: 38/100 with 10 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score

Get the complete analysis for ACRS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.04
Price
$0.45
GF Value